(Alliance News) -Â Oxford Biomedica PLC on Tuesday said it has signed a new three-year development and supply agreement with Boehringer Ingelheim for various types of viral vectors.
Ingelheim, Germany-headquartered Boehringer Ingelheim is a research-driven pharmaceutical company.
Under the pact, Oxford Biomedica intends to manufacture GMP batches for Boehringer Ingelheim to support the development of viral vectors. The deal also allows for Oxford Biomedica to manufacture and supply viral vector products in the future.
Oxford Biomedica Chief Executive John Dawson said: "This development and supply agreement with Boehringer Ingelheim demonstrates the good progress made in our partnership with Boehringer Ingelheim, which started in 2018. We are proud to be supporting another global pharmaceutical company in the development and manufacturing of their viral vector programs."
Shares in gene and cell therapy company Oxford Biomedica were up 2.2% at 973.00 pence in London on Tuesday.
By Lucy Heming;Â lucyheming@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Oxford Biomedica (OXB)